Top news of the week: 28.04.2020.
Biotechnology, Medicine, Naturalization, Dot-com bubble, Senescence, Candidate
Startups
RT @LifeSciVC: Immigration is essential for our world-leading biotech industry. And integrating immigrants into American culture adds enormous societal value.
At least half of our biotech CEOs are/have been immigrant to USA (2018 post): https://t.co/CiExXf8Gwz
h/t @JFruehauf @bernatolle
OpenCaravans of Biotech Immigrant Executives
Recently there’s been talk of a caravan of immigrants marching towards the United States, principally focused on Mexico and Central America. But there’s also another caravan, this one at ...
Inside the tiny Italian biotech startup racing to develop a coronavirus vaccine
https://t.co/2v20w9zShV By @giacomotognini https://t.co/T5NXAY0qDC
OpenInside The Tiny Italian Biotech Startup Racing To Develop A Coronavirus Vaccine
Takis Biotech, a small biotech outfit with only 25 employees based outside Rome, is hard at work on several candidates for a COVID-19 vaccine.
RT @IAmBiotech: BIO CEO @JimGreenwood one-on-one with BIO Chairman @jmaxlevin on hope for new solutions to #COVID19 https://t.co/jEwymUvpzb
OpenOne-On-One with Dr. Jeremy Levin on biotech’s “finest hour”
With America’s scientists and researchers working around the clock to eradicate COVID-19, BIO President and CEO Jim Greenwood checked in with Dr. Jeremy Levin. Dr. Levin is CEO of Ovid ...
AbbVie & Sofinnova led $38M A round in SF-based Nitrome Biosciences. Dementia Discovery Fund, Mission Bay, & Alexandria invested 2. Working on Parkinson's disease by targeting new enzymes class. CEO/CSO is Irene G. Prenner (Imago, iPierian, Elan) https://t.co/o2qLFVW6gj Congrats
OpenAbbVie, Sofinnova back $38M round for Parkinson's-focused Nitrome
What do Parkinson’s disease and diabetes have in common? Nitrome Biosciences thinks it can treat both, along with other aging-related diseases, by targeting a new class of enzymes—and it’s ...
Welcome to GV. @accent_tx advances the development of novel therapies by targeting RNA-modifying proteins / @schenkein – https://t.co/5rYB8bJw6A
OpenAccent Therapeutics nabs $63M for RNA cancer push
Two years ago, Accent Therapeutics got off a $40 million series A to target RNA-modifying proteins in cancer; now, in the middle of a pandemic, it’s still managed to bring in a respectable ...
Pfizer and new partner BioNTech nab approval to start closely watched COVID-19 vax trial https://t.co/Hw4WZXZGpS https://t.co/1644o7tsrx
OpenPfizer and new partner BioNTech nab approval to start closely watched COVID-19 vax trial
Pfizer has been granted approval in partner BioNTech’s native country Germany to kick-start a phase 2 test of their experimental mRNA vaccine for COVID-19.
Researchers have found possible avenues to treat dyskeratosis congenita and other diseases wherein cells age too early.
@DanaFarberNews https://t.co/Ky1BvmonKF
OpenPotential New Therapies for Telomere Diseases Identified
Using cells donated by patients with dyskeratosis congenita (DC), the researchers from the Dana-Farber/Boston Children's Cancer and Blood Disorders Center identified several small molecules ...
Life Science a VC Bright Spot in Q1, But Startups May Soon Struggle
- by @sarahdc
https://t.co/ONy1vztQl0
OpenLife Science a VC Bright Spot in Q1, But Startups May Soon Struggle
Even as the novel coronavirus has derailed daily life and business operations, the life sciences sector continues to see companies make public debuts and